HAEM5:T-prolymphocytic leukaemia: Difference between revisions
| [unchecked revision] | [unchecked revision] |
| Line 119: | Line 119: | ||
|D, P, T | |D, P, T | ||
|No | |No | ||
|Frequent, Minor diagnostic criteria.<ref name=":6" />PARP inhibitors may be considered as an off-label therapy | |Frequent, Minor diagnostic criteria.<ref name=":6" />PARP inhibitors may be considered as an off-label therapy (NCT03263637) | ||
|- | |- | ||
|12 | |12 | ||
| Line 195: | Line 195: | ||
|Common | |Common | ||
|D,P | |D,P | ||
| | |No | ||
| | |Major diagnostic criteria, the most frequent cooperating lesion <ref name=":6" /> | ||
|}<br /> | |}<br /> | ||
==Gene Mutations (SNV/INDEL)== | ==Gene Mutations (SNV/INDEL)== | ||
| Line 208: | Line 208: | ||
!Clinical Relevance Details/Other Notes | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
| | |''ATM'' | ||
<br /> | <br /> | ||
| | |Mutation/deletion | ||
| | |Tumor suppressor | ||
|<span class="blue-text">EXAMPLE:</span> Common (lung cancer) | |<span class="blue-text">EXAMPLE:</span> Common (lung cancer) | ||
|<span class="blue-text">EXAMPLE:</span> T | |<span class="blue-text">EXAMPLE:</span> T | ||